Track doses, log side effects, hit your protein goals, and see your progress. Everything you need for Ozempic, in one app.
“I finally feel like I have a handle on everything. The protein tracking alone changed how I eat.”
Sarah, 38
“My doctor was impressed I had everything logged. Side effects, doses, weight. Made the appointment so much more productive.”
Amy, 46
7-day free trial. Cancel anytime.
AI Protein Tracking
Take a photo of your meal and Lina breaks it down. Protein, calories, and macros in seconds. On Ozempic, getting enough protein is everything. Lina makes it effortless.
Side Effect Logging
Nausea, fatigue, headaches. Ozempic side effects can be confusing. Log what you feel, when you feel it, and start spotting patterns your doctor will actually want to see.
Injection Reminders
Set reminders for your Ozempic injection day. Track which site you used, rotate properly, and keep a clean record of every dose.
Daily Insights
Not generic wellness tips. Real, clinically-reviewed content written specifically for people on Ozempic. From what to eat to how to manage plateaus.
Weight Tracking
Weight fluctuates. Lina shows you the trend, not the noise. See your progress over weeks and months, overlaid with your dose timeline so you can see what is working.
Everything Included
Ozempic (semaglutide) is one of the most widely prescribed GLP-1 receptor agonists in the world. In the SUSTAIN-1 trial, participants on the 1 mg dose lost an average of 3.7 kg (8.2 lbs) over 30 weeks, alongside significant improvements in blood sugar control.
Beyond weight loss, the SUSTAIN-6 trial demonstrated a 26% reduction in major cardiovascular events over 2 years, making Ozempic one of the first GLP-1 medications to show meaningful heart health benefits.
Ozempic is primarily prescribed for type 2 diabetes, but its weight loss effects have made it one of the most talked-about medications globally. Regardless of why you are taking it, tracking your doses, side effects, and nutrition is key to getting the most from your treatment.
References:
Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol 2017;5(4):251-260.
Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375(19):1834-1844.